ArticleScientific reports2017
Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Anti-inflammatory action of fluvoxamine in an endotoxin-induced uveitis rat model: Histopathological evidence.Molecular vision · 2026Article
- Constructed transferrin receptor-targeted liposome for the delivery of fluvoxamine to improve prognosis in a traumatic brain injury mouse model.Drug delivery · 2025Article
- Potential Ameliorating Effects of Fluvoxamine in a Rat Model of Endotoxin-Induced Neuroinflammation: Molecular Aspects Through SIRT-1/GPX-4 and HMGB-1 Signaling.Molecular neurobiology · 2025Article
- Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability.Molecular psychiatry · 2024Article
- The IRE1α-XBP1 arm of the unfolded protein response is a host factor activated in SARS-CoV-2 infection.Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis.Brain, behavior, & immunity - health · 2024Review
- Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes.Molecular medicine (Cambridge, Mass.) · 2024Article
- Immunothrombosis in neurovascular disease.Research and practice in thrombosis and haemostasis · 2024Article
- Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.CNS drugs · 2023Review
- Review
- Fluvoxamine ameliorates oxidative stress and inflammation induced by bile-duct ligation in male rats.Heliyon · 2022Article
- Lactobacillus reuteri tryptophan metabolism promotes host susceptibility to CNS autoimmunity.Microbiome · 2022Article
- A Novel Role of Nogo Proteins: Regulating Macrophages in Inflammatory Disease.Cellular and molecular neurobiology · 2022Review
- Mechanisms of action of fluvoxamine for COVID-19: a historical review.Molecular psychiatry · 2022Review
- Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.International journal of molecular sciences · 2022Review
- Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.Current neuropharmacology · 2022Article
- Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.Frontiers in pharmacology · 2021Article
- Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants.Frontiers in pharmacology · 2021Article
- Antidepressants on Multiple Sclerosis: A Review ofFrontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) require medications controlling severity of the pathology and depression, affecting more than half of the patients. In this study, the effect of antidepressant drug fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in vitro and in vivo. Nanomolar concentrations of fluvoxamine significantly increased cell viability and proliferation of neural stem cells (NSCs) through increasing mRNA expression of Notch1, Hes1 and Ki-67, and protein levels of NICD. Also, physiological concentrations of fluvoxamine were optimal for NSC differentiation toward oligodendrocytes, astrocytes and neurons. In addition, fluvoxamine attenuated experimental autoimmune encephalomyelitis (EAE) severity, a rat MS model, by significantly decreasing its clinical scores. Moreover, fluvoxamine treated EAE rats showed a decrease in IFN-γ serum levels and an increase in IL-4, pro- and anti-inflammatory cytokines respectively, compared to untreated EAE rats. Furthermore, immune cell infiltration and demyelination plaque significantly decreased in spinal cords of fluvoxamine-treated rats, which was accompanied by an increase in protein expression of MBP and GFAP positive cells and a decrease in lactate serum levels, a new biomarker of MS progression. In summary, besides its antidepressant activity, fluvoxamine stimulates proliferation and differentiation of NSCs particularly toward oligodendrocytes, a producer of CNS myelin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.